LambdaGen Therapeutics
Singapore, Singapore· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Platform biotech using λ‑integrase for precise, large‑payload genome insertion to create next‑gen cell‑therapy and protein‑production solutions.
OncologyImmunology
Technology Platform
LIGIT is a λ‑integrase mediated site‑specific recombination system that enables precise insertion of large DNA cassettes into safe‑harbor or engineered landing‑pad loci in human cells, allowing seamless genome engineering without viral vectors.
Opportunities
Licensing of LIGIT for non‑viral gene integration and expansion of off‑the‑shelf CAR‑NK therapies could drive rapid revenue and strategic partnerships.
Risk Factors
Technical scalability of large‑payload integration and regulatory acceptance of engineered cell products remain key uncertainties.
Competitive Landscape
LambdaGen competes with viral‑vector and CRISPR‑based platforms (e.g., Cellectis, Sangamo) but differentiates through its λ‑integrase system that enables larger, safer insertions and a versatile service offering.